Published in Mol Cells on November 10, 2015
DNA Demethylation of the Foxp3 Enhancer Is Maintained through Modulation of Ten-Eleven-Translocation and DNA Methyltransferases. Mol Cells (2016) 0.76
TET family dioxygenases and DNA demethylation in stem cells and cancers. Exp Mol Med (2017) 0.75
Tumor necrosis factor-α decreases EC-SOD expression through DNA methylation. J Clin Biochem Nutr (2017) 0.75
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science (2009) 32.97
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65
Mutation in TET2 in myeloid cancers. N Engl J Med (2009) 16.07
DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet (2008) 15.45
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science (2011) 14.29
Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science (2011) 13.16
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell (2010) 13.13
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell (2011) 11.44
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell (2011) 9.16
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature (2010) 8.87
The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. Nature (2007) 8.17
The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. PLoS One (2010) 8.10
Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet (2009) 8.03
UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science (2007) 7.90
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell (2011) 7.37
Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood (2013) 6.50
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med (2010) 5.68
TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell (2011) 5.28
Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res (2007) 5.13
Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol Cell (2011) 4.89
Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet (2011) 4.85
Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine: potential implications for active demethylation of CpG sites. J Biol Chem (2011) 4.64
Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood (2011) 4.35
TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia (2003) 4.17
Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives. Cell (2013) 4.16
Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. Cell Cycle (2009) 4.14
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature (2012) 4.04
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia (2013) 3.93
LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res (2002) 3.73
Recognition of hemi-methylated DNA by the SRA protein UHRF1 by a base-flipping mechanism. Nature (2008) 3.62
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia (2009) 3.49
Structural basis for recognition of hemi-methylated DNA by the SRA domain of human UHRF1. Nature (2008) 3.39
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet (2012) 3.33
The SRA domain of UHRF1 flips 5-methylcytosine out of the DNA helix. Nature (2008) 3.28
Common 4q24 deletion in four cases of hematopoietic malignancy: early stem cell involvement? Leukemia (2005) 3.23
TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat Rev Mol Cell Biol (2013) 3.18
Reversing DNA methylation: mechanisms, genomics, and biological functions. Cell (2014) 3.17
Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci U S A (2011) 3.07
MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell (2013) 2.92
Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. Nature (2013) 2.76
Recognition and potential mechanisms for replication and erasure of cytosine hydroxymethylation. Nucleic Acids Res (2012) 2.55
5-Hydroxymethylcytosine is a predominantly stable DNA modification. Nat Chem (2014) 2.54
Thymine DNA glycosylase specifically recognizes 5-carboxylcytosine-modified DNA. Nat Chem Biol (2012) 2.45
TET1 is a tumor suppressor of hematopoietic malignancy. Nat Immunol (2015) 2.44
Mammalian cytosine methylation at a glance. J Cell Sci (2009) 2.43
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood (2010) 2.40
Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet (2014) 2.34
The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell (2013) 2.33
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood (2012) 2.23
Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet (2014) 2.14
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood (2013) 2.14
TET1 is a DNA-binding protein that modulates DNA methylation and gene transcription via hydroxylation of 5-methylcytosine. Cell Res (2010) 2.11
TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med (2012) 1.93
Ascorbic acid enhances Tet-mediated 5-methylcytosine oxidation and promotes DNA demethylation in mammals. J Am Chem Soc (2013) 1.90
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood (2012) 1.85
WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation. Mol Cell (2015) 1.79
Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature (2015) 1.76
Tet3 CXXC domain and dioxygenase activity cooperatively regulate key genes for Xenopus eye and neural development. Cell (2012) 1.76
Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med (2013) 1.71
ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol (2010) 1.71
HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc Natl Acad Sci U S A (2013) 1.70
5-formylcytosine and 5-carboxylcytosine reduce the rate and substrate specificity of RNA polymerase II transcription. Nat Struct Mol Biol (2012) 1.67
Clonal architecture of chronic myelomonocytic leukemias. Blood (2013) 1.67
Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature (2013) 1.65
Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation. Cell (2013) 1.63
Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood (2012) 1.60
A screen for hydroxymethylcytosine and formylcytosine binding proteins suggests functions in transcription and chromatin regulation. Genome Biol (2013) 1.50
Distinct roles of the methylcytosine oxidases Tet1 and Tet2 in mouse embryonic stem cells. Proc Natl Acad Sci U S A (2014) 1.50
Ascorbate induces ten-eleven translocation (Tet) methylcytosine dioxygenase-mediated generation of 5-hydroxymethylcytosine. J Biol Chem (2013) 1.43
5mC oxidation by Tet2 modulates enhancer activity and timing of transcriptome reprogramming during differentiation. Mol Cell (2014) 1.42
Inhibition of the Wnt signaling pathway by Idax, a novel Dvl-binding protein. Mol Cell Biol (2001) 1.36
Mechanism and function of oxidative reversal of DNA and RNA methylation. Annu Rev Biochem (2014) 1.36
Natural history of eukaryotic DNA methylation systems. Prog Mol Biol Transl Sci (2011) 1.35
Mechanism and stem-cell activity of 5-carboxycytosine decarboxylation determined by isotope tracing. Angew Chem Int Ed Engl (2012) 1.34
IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica (2010) 1.32
DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep (2014) 1.31
The mammalian de novo DNA methyltransferases DNMT3A and DNMT3B are also DNA 5-hydroxymethylcytosine dehydroxymethylases. J Biol Chem (2012) 1.30
An extensive network of TET2-targeting MicroRNAs regulates malignant hematopoiesis. Cell Rep (2013) 1.29
Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell (2015) 1.25
Connections between TET proteins and aberrant DNA modification in cancer. Trends Genet (2014) 1.24
Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J Exp Med (2013) 1.23
Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell (2014) 1.23
5-Formylcytosine can be a stable DNA modification in mammals. Nat Chem Biol (2015) 1.20
Molecular basis for 5-carboxycytosine recognition by RNA polymerase II elongation complex. Nature (2015) 1.20
TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci U S A (2013) 1.19
Role of Tet proteins in enhancer activity and telomere elongation. Genes Dev (2014) 1.19
TET proteins and 5-methylcytosine oxidation in hematological cancers. Immunol Rev (2015) 1.18
MicroRNA-26a targets ten eleven translocation enzymes and is regulated during pancreatic cell differentiation. Proc Natl Acad Sci U S A (2013) 1.14
Genomic 5-hydroxymethylcytosine levels correlate with TET2 mutations and a distinct global gene expression pattern in secondary acute myeloid leukemia. Leukemia (2011) 1.12
Differential regulation of the ten-eleven translocation (TET) family of dioxygenases by O-linked β-N-acetylglucosamine transferase (OGT). J Biol Chem (2014) 1.11
Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PLoS One (2012) 1.11
Tet2 disruption leads to enhanced self-renewal and altered differentiation of fetal liver hematopoietic stem cells. Sci Rep (2012) 1.04
TET2 is essential for survival and hematopoietic stem cell homeostasis. Leukemia (2012) 1.04
Wilms tumor protein recognizes 5-carboxylcytosine within a specific DNA sequence. Genes Dev (2014) 1.02
5-Formylcytosine alters the structure of the DNA double helix. Nat Struct Mol Biol (2014) 1.00